Cure8 news brief
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing Crohn's disease — results that motivated a larger Phase 2b trial.
Patients with fibrostenosing Crohn's disease, clinicians treating stricturing CD, IBD researchers, and patient advocates interested in antifibrotic or gut-restricted therapies.
Agomab reported
results come from a company-reported open-label extension and a financial-news summary; full methods, definitions, and complete safety data have not yet been published. Open-label data can suggest promise but are not definitive evidence of efficacy.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
